Sanara Medtech Inc. (SMTI) — SEC Filings
Sanara Medtech Inc. (SMTI) — 35 SEC filings. Latest: ARS (Apr 17, 2026). Includes 22 8-K, 5 10-Q, 2 DEFA14A.
View Sanara Medtech Inc. on SEC EDGAR
Overview
Sanara Medtech Inc. (SMTI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 24, 2026: Sanara MedTech Inc. filed an 8-K on March 24, 2026, reporting under Item 2.02, "Results of Operations and Financial Condition." This indicates the company is likely releasing its latest financial performance, which could include revenue, profit, or loss figures. Investors should pay close attention
Sentiment Summary
Across 35 filings, the sentiment breakdown is: 33 neutral, 2 mixed. The dominant filing sentiment for Sanara Medtech Inc. is neutral.
Filing Type Overview
Sanara Medtech Inc. (SMTI) has filed 1 ARS, 2 DEFA14A, 22 8-K, 5 10-Q, 2 DEF 14A, 2 10-K, 1 SC 13G with the SEC between Feb 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (35)
Risk Profile
Risk Assessment: Of SMTI's 28 recent filings, 2 were flagged as high-risk, 13 as medium-risk, and 13 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $26,333,819 |
| Net Income | -$30,411,153 |
| EPS | -$3.52 |
| Debt-to-Equity | 7.34 |
| Operating Margin | 11.17% |
| Total Assets | $71,088,648 |
| Total Debt | $45,089,787 |
Key Executives
- Chief Executive Officer
- Michael J. Collins
- David L. Johnson
- Dr. David L. Smith
- Dr. Michael J. Mulroy
- Mr. Robert E. Smith
- Michael J. O'Leary
Industry Context
Sanara MedTech operates in the medical technology sector, focusing on wound care and related solutions. The industry is characterized by innovation, regulatory oversight, and competition from both established players and emerging companies. Trends include a growing demand for advanced wound care products driven by an aging population and increasing prevalence of chronic diseases.
Top Tags
8-K (6) · financials (5) · executive-compensation (4) · management-change (3) · financial-reporting (3) · corporate-governance (3) · 10-Q (3) · Sanara MedTech (3) · financial-condition (2) · results-of-operations (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net loss attributable to Sanara MedTech shareholders | $30,411,153 | For the three months ended September 30, 2025, significantly higher than $2,857,768 in 2024. |
| Asset impairment charge | $26,472,407 | Related to discontinued operations in Q3 2025. |
| Net Revenue from continuing operations | $26,333,819 | For the three months ended September 30, 2025, up 21.5% from $21,671,599 in 2024. |
| Operating income from continuing operations | $2,941,240 | For the three months ended September 30, 2025, a significant improvement from $778,537 in 2024. |
| Long-term debt | $45,089,787 | As of September 30, 2025, an increase from $30,689,290 at December 31, 2024. |
| Total shareholders' equity | $6,140,534 | As of September 30, 2025, a sharp decline from $38,911,962 at December 31, 2024. |
| Interest expense | $1,818,105 | For the three months ended September 30, 2025, more than double the $927,577 from 2024. |
| Total assets | $71,088,648 | As of September 30, 2025, down from $88,091,992 at December 31, 2024. |
| Basic EPS from continuing operations | $0.10 | For the three months ended September 30, 2025, a positive shift from $(0.02) in 2024. |
| Basic EPS from net loss | $(3.52) | For the three months ended September 30, 2025, significantly worse than $(0.34) in 2024. |
| Net Revenue (Q2 2025) | $25.83M | Increased 28.1% from $20.16M in Q2 2024 |
| Net Revenue (H1 2025) | $49.26M | Increased 27.3% from $38.70M in H1 2024 |
| Net Loss (Q2 2025) | $(2.01M) | Improved from $(3.53M) in Q2 2024 |
| Net Loss (H1 2025) | $(5.55M) | Slightly higher than $(5.33M) in H1 2024 |
| Long-term Debt | $44.22M | Increased from $30.69M at Dec 31, 2024 |
Frequently Asked Questions
What are the latest SEC filings for Sanara Medtech Inc. (SMTI)?
Sanara Medtech Inc. has 35 recent SEC filings from Feb 2024 to Apr 2026, including 22 8-K, 5 10-Q, 2 DEFA14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SMTI filings?
Across 35 filings, the sentiment breakdown is: 33 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Sanara Medtech Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Sanara Medtech Inc. (SMTI) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Sanara Medtech Inc.?
Key financial highlights from Sanara Medtech Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SMTI?
The investment thesis for SMTI includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Sanara Medtech Inc.?
Key executives identified across Sanara Medtech Inc.'s filings include Chief Executive Officer, Michael J. Collins, David L. Johnson, Dr. David L. Smith, Dr. Michael J. Mulroy and 2 others.
What are the main risk factors for Sanara Medtech Inc. stock?
Of SMTI's 28 assessed filings, 2 were flagged high-risk, 13 medium-risk, and 13 low-risk.
What are recent predictions and forward guidance from Sanara Medtech Inc.?
Forward guidance and predictions for Sanara Medtech Inc. are extracted from SEC filings as they are enriched.